Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancerShunichi Sugawara, Kazuhiko Nakagawa, K.H. Lee et al.|Annals of Oncology|2021Cited by 202
LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2Jeffrey D. Bradley, Mustafa Özgüroğlu, Shunichi Sugawara et al.|ESMO Open|2024Cited by 74
LBA54 Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLCJS Lee, Kazuhiko Nakagawa, Shunichi Sugawara et al.|Annals of Oncology|2020Cited by 14